Fibronectin’s new implications in wound healing + Akron to present course at Amgen’s Bioprocessing Center
Following on from last week’s post on our capabilities to exclusively derive virus-inactivated fibronectin as the first such type of fibronectin on the market, this week we want to expand and highlight two new studies that have implicated fibronectin as having key roles in wound repair.
As widely known, fibronectin is one of the key proteins of the extracellular matrix, and has significant implications in wound healing and repair as well as cell growth. In brief, during the wound healing process, fibroblasts grow and produce fibronectin as well as other protein such as collagen that form a new extracellular matrix to fill the wound bed. This process has been studies extensively, as has fibronectin’s key role in cellular adhesion and growth. Two new studies highlight how fibronectin can be implicated, positively or negatively, in both wound healing as well as cell growth processes.
The first study, by Dr. Jonathan Garlick’s lab at Tuft’s University, is titled
Altered ECM deposition by diabetic foot ulcer-derived fibroblasts implicates fibronectin in chronic wound repair and is published in Cellular Reprogramming.
The authors investigated the wound healing process of diabetic foot ulcers (DFUs). DFU-derived fibroblasts were compared to healthy ones in their ability to generate the ECM during the wound repair process. the authors discovered that fibronectin generated by DFUs was deficient in its ability to promote growth factor beta regeneration, indicating it as they key protein regulating the process.
The second study looks at the role of fibronectin from a biomaterials perspective. Titled ”
Fibronectin-modified surfaces for evaluating the influence of cell adhesion on sensitivity of leukemic cells to siRNA nanoparticles,” it was published by the lab of Dr. Hasan Uludağ at the University of Alberta in Canada in the journal Nanomedicine. The authors have demonstrated that fibronectin (FN)-grafted (by crosslinking), plasma-treated PTFE surfaces can be used as suitable platforms to investigate the influence of leukemic cell adhesion on siRNA treatment. Improved adhesion and growth of chronic myeloid leukemia K562 cells was possible on FN-grafted surfaces.
Akron at Amgen Bioprocessing Center
We are pleased to announce that Akron Biotech will participate in an industrial/academic training course at the Amgen Bioprocessing Center at the Keck Graduate Institute in Clermont, CA. Akron will lecture participating delegates, who will attend an intensive hands-on course on Bioprocessing, on proteins and their use in bioprocessing – from structure and function to purification techniques and analytical measurements. The course starts on September 19th.